Aptorum Group Limited and DiamiR Biosciences Form New Alliance
Aptorum Group Limited (NASDAQ: APM), a clinical stage biopharmaceutical company known for its innovative approach to treating unmet medical needs, has taken a significant step forward through its recent merger agreement with DiamiR Biosciences. This collaboration was established to unite their strengths and better serve the landscape of healthcare specifically in the realm of oncology and brain health.
The Merger Agreement Unveiled
The merger, which is structured as an all-stock transaction, will see DiamiR operate as a wholly-owned subsidiary of Aptorum Group and maintain its brand identity following the merger's completion. This partnership aims to leverage DiamiR's pioneering work in developing proprietary blood-based tests for brain health and its broader clinical offerings.
Comments from Leadership
Ian Huen, the Chief Executive Officer and Chairman of Aptorum, emphasized the merger's potential to create substantial value for shareholders. He stated, "Combining forces with DiamiR, a company focused on significant unmet health needs, positions us on a path to build a global life sciences enterprise capable of generating much-needed insights through biomarker panels. This merger offers us both immediate and long-lasting advantages in the competitive biomedical market.
DiamiR's Perspective
Alidad Mireskandari, Ph.D., the Chief Executive Officer of DiamiR, expressed enthusiasm about the merger's strategic fit. He noted the importance of aligning their capabilities to enhance clinical and pharmaceutical services targeting aging-related diseases, including neurodegenerative conditions like Alzheimer's, as well as various oncology and autoimmune disorders. This alliance is set to establish the combined entity as a leading innovator in non-invasive testing solutions.
Transaction Details and Approval Process
Under the agreed terms, Aptorum Group plans to re-domicile to Delaware. After this process, it will acquire all outstanding shares of DiamiR in a deal expected to have significant implications for both companies. Current Aptorum shareholders will hold approximately 30% of the merged entity’s stock, signifying a strategic redistribution intended to foster growth and innovation.
Looking Ahead
The leadership teams from both companies will preside over the new organization, with Huen continuing as CEO and DiamiR’s Mireskandari stepping in as President and Chief Operating Officer. The combined board will consist of five members, ensuring a balanced representation from both original companies.
Shareholder Engagement and Future Outlook
Aptorum is preparing to seek shareholder approval for the merger and related actions, including the re-domiciliation and a possible reverse stock split. Important regulatory milestones, such as satisfying NASDAQ's listing requirements and the SEC's approval of the registration statement for share issuance, must be achieved ahead of the merger's closing, anticipated in the last quarter.
Legal and Financial Representation
For the merger process, Aptorum has enlisted Hunter Taubman Fischer & Li LLC, while Ellenoff Grossman & Schole LLP is representing DiamiR. Financial advisory services for DiamiR are provided by H.C. Wainwright & Co., highlighting a strong professional support network for this critical transition.
About Aptorum Group
Aptorum Group Limited (NASDAQ: APM) is dedicated to the discovery and development of therapies aimed at treating diseases with significant unmet medical needs. It works specifically within oncology and infectious diseases, striving to bring innovative solutions to the market.
About DiamiR Biosciences
DiamiR is committed to improving patient outcomes through its ground-breaking tests designed for early detection and ongoing monitoring of brain health and related conditions. Its proprietary technology is safeguarded by a robust portfolio of patents and is complemented by collaborations with prestigious academic institutions and industry partners.
Frequently Asked Questions
What is the primary focus of Aptorum Group?
Aptorum Group is focused on developing treatment solutions for unmet medical needs, particularly in oncology and infectious diseases.
What does the merger with DiamiR mean for Aptorum Group's future?
The merger aims to enhance Aptorum's capabilities and market presence, particularly in the areas of brain health and complex disease testing.
Who will lead the combined company after the merger?
The combined company will be led by Ian Huen as CEO, with Alidad Mireskandari taking on the role of President and COO.
What regulatory approvals are required for the merger?
The merger requires both companies' shareholder approvals, compliance with NASDAQ listing requirements, and SEC approval on the registration statement.
When is the expected closing date for the merger?
The merger is anticipated to close in the fourth quarter of the year, pending regulatory and shareholder approvals.
